Stock Track | Asymchem Soars 5.87% in Afternoon Session on 2 Billion Yuan CDMO Project Expansion

Stock Track04-24

Asymchem's stock price surged 5.87% during intraday trading, reflecting significant positive investor sentiment.

The sharp rise follows the company's announcement of signing a memorandum of cooperation with the Tianjin Economic-Technological Development Area Administrative Committee. The agreement involves expanding a CDMO (Contract Development and Manufacturing Organization) research and production base for innovative chemical macromolecule drugs, with a total projected investment of 2 billion yuan. This expansion is expected to significantly enhance Asymchem's integrated service capabilities for new molecular types like peptides and oligonucleotides.

The company's chemical macromolecule CDMO segment has been its fastest-growing business unit, reporting operating revenue of 1.028 billion yuan in 2025, a year-on-year increase of 123.72%. The new project aligns with this growth trajectory and is anticipated to support future capacity increases and project development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119604332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119604332","market":"nz","top_or_hot":-1,"title":"Stock Track | Asymchem Soars 5.87% in Afternoon Session on 2 Billion Yuan CDMO Project Expansion","media":"Stock Track","content":"<p>Asymchem's stock price surged 5.87% during intraday trading, reflecting significant positive investor sentiment.</p><p>The sharp rise follows the company's announcement of signing a memorandum of cooperation with the Tianjin Economic-Technological Development Area Administrative Committee. The agreement involves expanding a CDMO (Contract Development and Manufacturing Organization) research and production base for innovative chemical macromolecule drugs, with a total projected investment of 2 billion yuan. This expansion is expected to significantly enhance Asymchem's integrated service capabilities for new molecular types like peptides and oligonucleotides.</p><p>The company's chemical macromolecule CDMO segment has been its fastest-growing business unit, reporting operating revenue of 1.028 billion yuan in 2025, a year-on-year increase of 123.72%. The new project aligns with this growth trajectory and is anticipated to support future capacity increases and project development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Asymchem Soars 5.87% in Afternoon Session on 2 Billion Yuan CDMO Project Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Asymchem Soars 5.87% in Afternoon Session on 2 Billion Yuan CDMO Project Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-24 14:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Asymchem's stock price surged 5.87% during intraday trading, reflecting significant positive investor sentiment.</p><p>The sharp rise follows the company's announcement of signing a memorandum of cooperation with the Tianjin Economic-Technological Development Area Administrative Committee. The agreement involves expanding a CDMO (Contract Development and Manufacturing Organization) research and production base for innovative chemical macromolecule drugs, with a total projected investment of 2 billion yuan. This expansion is expected to significantly enhance Asymchem's integrated service capabilities for new molecular types like peptides and oligonucleotides.</p><p>The company's chemical macromolecule CDMO segment has been its fastest-growing business unit, reporting operating revenue of 1.028 billion yuan in 2025, a year-on-year increase of 123.72%. The new project aligns with this growth trajectory and is anticipated to support future capacity increases and project development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06821","symbol_name":"凯莱英","start_time":0,"source_url":"","article_id":"1119604332","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119604332","pubTimestamp":1777012179,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Asymchem's stock price surged 5.87% during intraday trading, reflecting significant positive investor sentiment.The sharp rise follows the company's announcement of signing a memorandum of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06821":"凯莱英"},"translate_title":"个股赛道|20亿元CDMO项目扩建凯莱英午盘大涨5.87%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06821":1},"content_text":"Asymchem's stock price surged 5.87% during intraday trading, reflecting significant positive investor sentiment.The sharp rise follows the company's announcement of signing a memorandum of cooperation with the Tianjin Economic-Technological Development Area Administrative Committee. The agreement involves expanding a CDMO (Contract Development and Manufacturing Organization) research and production base for innovative chemical macromolecule drugs, with a total projected investment of 2 billion yuan. This expansion is expected to significantly enhance Asymchem's integrated service capabilities for new molecular types like peptides and oligonucleotides.The company's chemical macromolecule CDMO segment has been its fastest-growing business unit, reporting operating revenue of 1.028 billion yuan in 2025, a year-on-year increase of 123.72%. The new project aligns with this growth trajectory and is anticipated to support future capacity increases and project development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119604332","isCrawlerRequest":true}